Saturday, July 12, 2025

Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection




News Story – QuoteMedia Market Data Solutions




Share: